Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Investment analysts at SunTrust Banks increased their FY2016 earnings estimates for shares of Jazz Pharmaceuticals PLC in a note issued to investors on Wednesday. SunTrust Banks analyst J. Boris now expects that the firm will post earnings per share of $6.70 for the year, up from their previous forecast of $6.56. SunTrust Banks also issued estimates for Jazz Pharmaceuticals PLC’s Q4 2016 earnings at $2.30 EPS, FY2017 earnings at $7.59 EPS, FY2018 earnings at $9.37 EPS, FY2019 earnings at $11.71 EPS and FY2020 earnings at $13.73 EPS.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.61 by $0.04. The firm had revenue of $374 million for the quarter, compared to analyst estimates of $389.34 million. Jazz Pharmaceuticals PLC had a net margin of 24.81% and a return on equity of 30.50%. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.52 earnings per share.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Several other brokerages also recently issued reports on JAZZ. BMO Capital Markets restated an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Sunday, July 31st. Barclays PLC restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 10th. Piper Jaffray Cos. lowered their price target on Jazz Pharmaceuticals PLC from $188.00 to $178.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Mizuho lowered their price target on Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Wednesday, July 20th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $178.25.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 112.35 on Monday. The company has a 50-day moving average price of $117.01 and a 200 day moving average price of $134.61. The firm has a market capitalization of $6.73 billion, a price-to-earnings ratio of 19.65 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $160.00.

In related news, SVP Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $126.17, for a total transaction of $25,234.00. Following the completion of the sale, the senior vice president now directly owns 17,325 shares of the company’s stock, valued at approximately $2,185,895.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Seamus Mulligan sold 27,968 shares of Jazz Pharmaceuticals PLC stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $128.32, for a total value of $3,588,853.76. Following the sale, the director now directly owns 1,072,411 shares of the company’s stock, valued at $137,611,779.52. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in JAZZ. Gateway Investment Advisers LLC purchased a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $4,820,000. British Columbia Investment Management Corp boosted its stake in Jazz Pharmaceuticals PLC by 8.8% in the second quarter. British Columbia Investment Management Corp now owns 32,727 shares of the specialty pharmaceutical company’s stock valued at $4,625,000 after buying an additional 2,637 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at $4,026,000. BlueMountain Capital Management LLC boosted its stake in Jazz Pharmaceuticals PLC by 72.7% in the first quarter. BlueMountain Capital Management LLC now owns 7,217 shares of the specialty pharmaceutical company’s stock valued at $942,000 after buying an additional 3,039 shares during the last quarter. Finally, Avalon Advisors LLC boosted its stake in Jazz Pharmaceuticals PLC by 13.7% in the first quarter. Avalon Advisors LLC now owns 9,320 shares of the specialty pharmaceutical company’s stock valued at $1,217,000 after buying an additional 1,120 shares during the last quarter. 87.60% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.